On May 8, KyungDong Pharm signed a joint development agreement with OWL Bio for AUL009, a long-acting semaglutide injection for obesity and diabetes. The agreement adds a once-monthly injectable treatment to the company’s pipeline. Semaglutide, the active ingredient in AUL009, is a glucagon-like peptide-1 (GLP-1) receptor agonist. Novo Nordisk’s Wegovy prefilled pen for obesity and Ozempic prefilled pen for diabetes, which contain the same active ingredient, have received approval from Korea’s Ministry of Food and Drug Safety. Both are administered once weekly. AUL009 is being developed to provide sustained activity for one month with a single injection. CEO Ryu Ki-sung said, “The joint development of AUL009 will further strengthen our strategic partnership with OWL Bio. We expect a once-monthly injection to offer an effective treatment option and help improve adherence and quality of life.” He added, “We will continue pursuing joint development and investment with technologically advanced biotechnology ventures to establish medium- and long-term growth. We plan further investment this year together with strategic investors.” KyungDong Pharm made a strategic investment in OWL Bio in 2022. This year, it also signed an additional strategic investment agreement alongside the AUL009 development agreement, continuing its focus on future growth.